Business Wire

COTY

21.4.2021 10:02:12 CEST | Business Wire | Press release

Share
Coty Lands Industry First With Sustainability Certificate for Lancaster Sun Care Products

Coty Inc. (NYSE: COTY), one of the world’s leading beauty companies and the global leader in fragrances, today announced that Lancaster has become the first ever sun care brand awarded the prestigious C2C Certified Material Health Certificate at the Silver level from the Cradle to Cradle Products Innovation Institute.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005237/en/

The award indicates that 100% of the ingredients in Lancaster Sun Sensitive collection –Lancaster’s first clean and vegan range, and its most environmentally friendly yet - meet the Institute’s strict criteria. In addition to recognizing the sustainable innovation behind the collection, the Certification serves as the foundation for further improving the sustainability and product safety of sun care products over time.

Lancaster Sun Sensitive collection provides broad sun protection* targeting 100% of sun spectrum through a clean, minimalistic** vegan formula providing even sensitive skin with a delicate golden glow, preserved from redness and discomfort. The products also feature an ocean friendly UV filter system*** - all delivered in eco-designed packaging.****

Sue Y. Nabi, Chief Executive Officer at Coty , said: “Sustainability is the ultimate driver of innovation and brands like Lancaster are creating outstanding products that are truly clean and green. Today’s consumer rightly expects that their favorite products also deliver when it comes to environmental performance. It’s our approach to product innovation that sets Coty apart and these industry firsts reflect the expertise of our teams and our brands.”

The C2C Certified Material Health Certificate by the Cradle to Cradle Products Innovation Institute offers a solution to growing industry and consumer interest in knowing more about the chemicals used in products across their supply chains and avoiding chemicals of concern. By using the rigorous, globally recognized material health assessment methodology of the Cradle to Cradle Certified Product Standard, the Material Health Certificate provides manufacturers with a trusted means of assessing, optimizing and verifying their product chemistries for safety and the environment. A C2C Certified Material Health Certificate is awarded to products that meet the Material Health requirements of the multi-attribute Cradle to Cradle Certified™ Product Standard. The certificate is valid for two years.

“Beyond leading the way in sun care with the first C2C Certified Material Health Certificate in the category, Coty is also paving the way towards greater product safety, transparency and innovation throughout the beauty industry ,” said Dr. Christina Raab, Vice President of Strategy and Development for the Cradle to Cradle Products Innovation Institute.

Laure Calvel, VP Global Marketing at Lancaster , said: “Receiving the Cradle to Cradle Products Innovation Institute’s Silver Level Material Health Certificate for our Sun Sensitive range is another positive step in demonstrating the safe use of materials that are circular and responsible in our products. We have a framework for improving the sustainability of all the products in our portfolio and very ambitious plans over the coming years.”

Product innovation is a crucial element of Coty’s journey to becoming a more circular business and creating a more sustainable and inclusive world – as set out in its Beauty That Lasts’ strategy. Today’s announcement builds on the success of Calvin Klein’s first clean and environmentally conscious fragrance, CK EVERYONE, which achieved a Material Health Certificate at the Silver level from the Cradle to Cradle Products Innovation Institute in April 2020.

Last month, Coty announced a partnership with LanzaTech to introduce sustainable ethanol made from captured-carbon emissions into its fragrance products. LanzaTech captures industrial emissions and processes the waste gases into a new, more sustainable source of ethanol that is suitable for use in fragrances. Coty has set the goal of having the majority of its fragrance portfolio using ethanol sourced from carbon-capture by 2023.

* No sunscreen product can provide full protection against sun’s rays. Overexposure to the sun is a dangerous health risk.
** Formulas contain on average 40% fewer ingredients than previous range/competitors.
*** In vitro test method established with the University of Nice Institute to assess the potential impact of a sunscreen product on cnidarian cells.
**** Tubes/bottles contain at minimum 50% post-consumer recycled materials.

About Coty Inc.

Coty is one of the world’s largest beauty companies with an iconic portfolio of brands across fragrance, color cosmetics, and skin and body care. Coty is the global leader in fragrance and number three in color cosmetics. Coty’s products are sold in over 150 countries around the world. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com .

About the Cradle to Cradle Products Innovation Institute

The Cradle to Cradle Products Innovation Institute is dedicated to powering innovation for the circular economy through products that have a positive impact on people and planet. Through the Cradle to Cradle Certified® Products Program, the Institute sets the global standard for products that are safe, circular and made responsibly. Cradle to Cradle Certified is used by many future-focused designers, brands, retailers and manufacturers across the value chain to innovate and optimize materials and products according to the world’s most advanced science-based measures for material health, product circularity, renewable energy and climate, water and soil stewardship, and social fairness. The Institute also powers the global shift to a circular economy through partnerships and collaborative initiatives that equip businesses, governments and other stakeholders with the technical solutions and knowledge they need to innovate the way products are designed and made. For more information about the Institute, visit c2ccertified.org. C2C Certified Material Health Certificate™ is a word mark licensed by the Cradle to Cradle Products Innovation Institute.

About Lancaster SUN SENSITIVE

Lancaster’s broadest sun protection respects the most sensitive skin’s needs:

  • Provides optimal protection with Full Light Technology, which targets 100% of sun spectrum (1) (UVB, UVA, Visible Light and Infrared rays).
  • Gives a luminous and long-lasting tan which develops gradually thanks to the exclusive natural origin Tan Activator Complex, which stimulates the natural tanning process for a never-ending summer.
  • Helps reduce redness and the feeling of discomfort while protecting sensitive skin from sun damage, thanks to the new natural origin Sunsicalm complex.
  • Respects marine life, with an ocean friendly UV filter system and water-resistant formulas, while being respectful for the skin with minimalistic (2), vegan formulas, all in eco-designed packaging (3).
  • Provides ultra-sensorial and lightweight textures yet clean, that penetrates easily without leaving white traces with a transparent finish after application and a clean labelled fragrance.
  • For children, a convenient face and body spray that meets all their needs (anti-sand, wet skin application, tearless formula, water resistant and fragrance-free).
  1. No sunscreen product can provide full protection against sun’s rays. Overexposure to the sun is a dangerous health risk.
  2. Formulas contain on average 40% fewer ingredients than previous range/competitors.
  3. Tubes/bottles contain at minimum 50% post-consumer recycled materials.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye